Stats

Premises:1 September18 issuer release announces20.35 cash acquisition by HIG affiliates,866m enterprise value including debt;31% support, majority vote/regulatory conditions. September17 agreement and September18 8K confirm no financing condition, committed funding subject terms, company fee27.514109m (half during qualifying go-shop) and parent fee49.869322m only specified triggers.2 October27 23:59ET go-shop is a solicitation deadline, not promised public bid announcement; closing expected late2026/early2027, outside June17 2027 with conditional September15 extension.3 Oct16P20 costs12 indicative and is below offer; offer anchoring changes standalone earnings/cash-to-price transmission. Old revenue growth cannot alone justify downside-tail probability after signed deal. Valid inference: old ordinary-breakout sample is not a calibrated announced-cash-deal sample. Counterexample: deal can fail, trade below offer before close, or get raised; no claim of guaranteed floor. Soundness: directly executed agreement for terms, issuer press for intent; both same originating transaction, not independent probability estimates. Facts end at terms/current quote; no empirical failure frequency established. Employee option cancellation clause is not OCC treatment for listed contracts. Reject transplant of prior14.19x target into live thesis; keep numerical old screen frozen. Sources https://www.sec.gov/Archives/edgar/data/1436126/000114036126037107/ef20082419_ex99-1.htm ; https://www.sec.gov/Archives/edgar/data/1436126/000114036126037107/ef20082419_8k.htm ; https://www.sec.gov/Archives/edgar/data/1436126/000114036126037107/ef20082419_ex2-1.htm .

Premises:1 HZO issuer Aug10 SEC exhibit https://www.sec.gov/Archives/edgar/data/1057060/000119312526341302/d135056dex991.htm specifies53cash/share. Sep18close52.56 leaves0.44 or0.837% to unchanged terms; C55 needs revised bid to finishITM. Pre-deal breakout tails are not stationary merger tails. 2 TORM Sep15 secondary9mshares for290.25m seller proceeds,0company cash;Sep18 Hafnia18.19% ownership. Originals https://www.torm.com/news/company-announcements/company-announcements-details/2026/TORM-plc-announces-pricing-of-secondary-public-offering-of-its-class-A-common-shares/default.aspx and https://www.torm.com/news/company-announcements/company-announcements-details/2026/Major-Shareholder-Announcement-34313618f/default.aspx . Strategic demand may persist, strongest countercase to flow reversal; no deal bid inferred. 3 Aug26TORM results showQ2EBITDA416m incl7m mark gains, Q3covered73% at38606/day versusQ2achieved59301/day. 10271openFYdays imply10.271mEBITDA per1000/day rate change, not fullfleet exposure. Issuer https://www.torm.com/news/company-announcements/company-announcements-details/2026/TORM-plc-Q2-2026-Results-Dividend-Distribution-and-Financial-Outlook-2026/default.aspx . Conclusion: no annualizing peakQ2 or calling secondary new financing income. HZO genericcalltail invalid under unchangeddeal; put requires explicitdealbreak distribution. TORM viablebreakoutresearch butaffordablelegs mustpass. Validity arithmetic sound; soundness futurebid/rates/stationarity unknown.

Premises:1 HALO issuer explicitly describes possible hedge purchases around financing;460m residual cash and16.92075m incremental annualcoupon do not identify customer demand. Bear: technical volume normalizes while distant call decays. Counterexample: operating royalty growth can sustain price after hedges finish; no actual dealer-flow attribution.2 TH company receives0 secondaryproceeds and funded1,693,599repurchasedshares with cash/ABL; bear: liquidity redistribution is mistaken for company cash growth. Counterexample: operating contracts can still add value; financing alone does not negate breakout.3 NKE Q4approx40.2%grossmargin excluding9pp expectedtariff-recovery benefit versus40.3%prior; EPS.20 excluding.52 benefit versus.14prior. Bear: reportedmargin overstates recurringprogress; counterexample wholesale+1%FXneutral and9bncash/investments permit recovery. Conclusion: retain conditional tailwatch, no target from conversion terms, headlines or operating distress alone. Full source figures observations30991–92/31055. Sources HALO issuer-authored https://www.prnewswire.com/news-releases/halozyme-therapeutics-inc-announces-pricing-of-upsized-private-offering-of-1-3-billion-of-convertible-senior-notes-due-2033--302882873.html ; TH issuer closing original observation30992; NKE https://www.sec.gov/Archives/edgar/data/320187/000032018726000076/q4fy26exhibit991er.htm

Premises:1 WORissuerJune23FY2026sales1.4bn+20%,acquisition121.7m/organic9%,adjustedEPS3.37,FCF170.2m+7%; Q4sales371.5m+17%,44.1macquisitions/3%organic,EPS.97vs1.06. AtS57.38trailingadjustedPE17.03,notfairvalue.2 MRKFeb3FY2025WINREVAIRsales1.4bn/company65bn=2.154%; Sep21HYPERIONlabelreview notinitialapproval; no6matchedlabel-eventstudyestablishedthisrun.3 Affordability bindsWOR beforevaluation: min67>30; MRKcheapOct2C162.5.16 needs10.751%up,matchingeventedgeunknown. Conclusion: dates qualifyresearch,notdeployment. Counterexample: smallreportedproductsharecanhavegreatergrowthvalue; declineinWORquarterlyEPSdespitesalesgrowthcanreflectmix/acquisitionexpenses. Neitherfactprovesdirection. Change mind onactualcash/orders/labelterms plusqualifiedattainablecontract. Sources https://ir.worthingtonenterprises.com/news/news-details/2026/Worthington-Enterprises-Reports-Fourth-Quarter-and-Full-Year-Fiscal-2026-Results/ ; https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/ ; MRKJune3010Qsource30855.

Premises:1 Sep17issueroriginal rereadHTTP200:1.3bn1.5%notes,1275mnet;162.5mcappedcalls,217m2027-note cashrepurchase,435.5m2028 repurchase.2 Residual460m,incrementannualcoupon19.5-.37925-2.2=16.92075m; expectedSep22closeconditional.3 Conversion139.84/cappedcall208.39 are contractualterms,notfairvalue. Conclusion: fundingextendsmaturity but cannotprove organicdemandbehind6.93xvolume; existingsettlementmonitor434appropriate. No new company valuation ortruehedgeposition inferred. Source https://ir.halozyme.com/news/news-details/2026/Halozyme-Therapeutics-Inc--Announces-Pricing-of-Upsized-Private-Offering-of-1-3-Billion-of-Convertible-Senior-Notes-due-2033/default.aspx

Premises:1 Sep17 HALO priced1.3bn1.5%notes, expectedSep22conditionalclose;1275mnet less162.5mcappedcalls and652.5mold-note cashrepurchases leaves460m,not1.3bnfreecash. Grossprincipal increases928.3m;annualcouponincrement16.92075m beforeotherdebtchanges.2 Issuer explicitly flags hedge purchases/old-note unwind aroundpricing; actualfractionofSep18volume unknown.3 THSep10secondary16.1mshares at18.50 producednocorporateproceeds;companyrepurchased1.693599msharesusingcashandABL. Conclusion: breakout eligibility persists,butvolume cannotbe countedasanindependentvoteoforganiccustomeracceleration. Strongcountercase: sustainedroyaltygrowth/contractconversion stilldrivetrend afterhedges; currentdata do notseparatecauses. Start100cash/1000equity;goalqualifiedsmalllongoption;bindingconstraint executableaffordablepremium andforecasttransportability. Noexactfutureearningsdateinvented. Sources https://ir.halozyme.com/news/news-details/2026/Halozyme-Therapeutics-Inc--Announces-Pricing-of-Upsized-Private-Offering-of-1-3-Billion-of-Convertible-Senior-Notes-due-2033/default.aspx and https://investors.targethospitality.com/news/news-details/2026/Target-Hospitality-Announces-Closing-of-Upsized-Secondary-Offering-and-Concurrent-Stock-Repurchase-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares/default.aspx . Settlementisfinancingmechanics,notdrugapproval; noautomaticpre-eventexit solelybecausepaymentsettlesSep22.

Premises:1 HALO June30 filing H1OCF420.969m versus253.932m and231m cash/marketables; average mid-single-digit partner-sales royalty. Aug6 issuer Q2revenue481m/royalties307.7m; adjustedEPSguide8.65–9 implies12.49–13.0x at112.45. Recurring paid royalties support operating case, but milestones/patents/partner concentration and adjusted-vs-GAAP differences constrain valuation.2 TH Aug10 Q2revenue85.5m(+39%),netloss9m,adjEBITDA18.2m;H1OCF111m dominated by customeradvances.1.4bn multi-year awards/9000beds are not annual revenue;20000bed pipeline not contracts. Sep10secondary16.1mshares at18.50 proceeds tosellingholders, not corporatecash.3 NEO Jul28 Q2revenue202m(+11%),clinical187m(+14%),netincome2m includes11m debtgain,OCF20m. Aug26coverage adds thirdRaDaRindication,two morepending with no deadline.4 HZO Aug10agreed53cash versus52.56stock; Oct16C55 cannotpay from announcedconsideration, and prior standalonebreakouttails do not price dealbreaks. Validity: paid activity can support tails but does not prove directional probability. Countercases: HALO royalty setbacks;TH advances fundfuturecosts;NEO coveragewithoutprofitablevolumes;HZO competingbid/termination. Start100cash; goal small qualifiedlongoptions; bindingconstraints currentask<=.30 and actualhistoricalcomparablepayoff. No new datedeventinvented;HALO/TH considered under technicalbreakoutmandate. Sources observations30001–4; NEO https://ir.neogenomics.com/news-events/press-releases/detail/336/neogenomics-reports-second-quarter-2026-results and /detail/337/neogenomics-receives-medicare-coverage-for-radar-st-for-immunotherapy-treatment-response-monitoring . Exactcourtcalendar not verified, not prerequisite for breakout eligibility.

Premises: observations29827/29828 recheck primary historical results, not newweekendearnings. SFIX shows sequential client recovery and liquidity withoutdebt; these undermine a distress put. Lower margins and buybacks exceedingquarterFCF keep execution risk relevant. LW cash generation improved substantially as capex fell, while international profitability weakened. Neither adjustedearnings decline nor lowshareprice alone establishes futuretail direction. Counterexamples: stabilization could drive gains; renewedpricecompetition could overwhelm savings. Validity: conditionalcash-to-equitymechanism is coherent. Soundness: futurecash and marketexpectations remain unmeasured. No position or exit reset; both current tickets fail the independentpremium/payoffgate. Sources https://investors.stitchfix.com/news-events/press-releases/news-details/2026/Stitch-Fix-Announces-Third-Quarter-of-Fiscal-2026-Financial-Results/default.aspx ; https://news.lambweston.com/news-releases/news-release-details/lamb-weston-announces-q4-and-full-year-fiscal-2026-results .

Premises:1 July15 issuer FY26 report https://www.conagrabrands.com/news-room/news-conagra-brands-reports-fourth-quarter-and-full-year-results-prn-122958 reports FCF978.7m vs1302.6m(-24.9%),netdebt7050.4m/leverage3.83x;FY27adjustedEPS1.40–1.50 andorganic sales-3%to-1%. 2 Sep18S15.13 gives10.09–10.81x guidedadjustedEPS; accountingadjustments andleverage prevent callingcheappriceamarginofsafety. 3 Guidance isissuerforecast, notconsensus surprise;cashgeneration materiallypositive despiteweakening. Conclusion bearcase requiresvolume/margin deterioration beyondpricedexpectations;bullcounterexample isstabilization plusdeleveraging. Incentives:managementbenefitsfromadjustedmetrics andturnaroundnarrative;creditorsbenefitfromcashretention. FCF/netdebt13.88%annual historicalflowratio, notdebtpayoffforecast orowner-equityyield. Priorneutraldirection; sustainedcashimprovement weakensputthesis, sharpcashandguide deterioration supportsdownsidebutstillrequiresqualifyingcontract. Valuationmultiples do not overridefailedtailgate.

Premises from June25 issuer SEC exhibit https://www.sec.gov/Archives/edgar/data/1070235/000107023526000071/q1fy27ex-991.htm : Q1 FY27 revenue152.9m+26%, QNX72.3m+26%, Secure Communications73.6m+24%, EBITDA36.3m, GAAPoperating15.3m. OCF4.6m is12.67% ofadjustedEBITDA; repurchases10m exceedOCF by5.4m even beforecapex. ARR220m stable/DBNRR92% means quarterly revenue growth cannot be read as universal recurring customer expansion. Cash/investments422.9m provide flexibility but do not establish equity floor; debt/leases/dilution not fully valued thisrun. Q2 guide137–148m revenue,20–30m EBITDA,0–10mOCF versusFY~100mOCF makes seasonality and collections consequential; annualizingQ1 wouldmislead. Prior direction neutral; credible recurring cash and strongerretention would improveupside thesis, a licensing-driven beat withoutcash would weakenit. Who benefits: license customers fromembeddedsoftware, management fromadjustedgrowth optics, shareholders fromactualresidualcash. Strongcounterargument toput: transformedpositivecashbusiness can rerate; strongestcall objection: a26%historicalgrowthrate is already disclosed and does notmeasure surprise. No valuation-derived target or directionalprobability justified. CatalystSep24 08EDTissuer https://investors.blackberry.com/ .

Premises: (1) Q3 June10 issuer baseline revenue340.277m+4.7%,active2.309m+.9%q/q yet-1.9%y/y,RPAC578+6.6%; forecasts Q4revenue322–327m and EBITDA7–10m. (2) FCF6.520m while repurchases15.1m: payout2.316xFCF, excess8.58m funded from balance sheet. (3) Cash+investments229.4m/no debt cushions a weak quarter but is not a contractual stock floor. (4) June5 filing shares133.425856m times Sep18 S2.84 implies illustrative equity378.929m/enterprise149.529m excluding lease obligations; cash1.719/share, FYguidedEBITDA midpoint50.5m gives EV/EBITDA2.961x. These mix June share/cash vintage with September price; not a live valuation or liquidating value. Evidence: https://investors.stitchfix.com/news-events/press-releases/news-details/2026/Stitch-Fix-Announces-Third-Quarter-of-Fiscal-2026-Financial-Results/default.aspx ; https://www.sec.gov/Archives/edgar/data/1576942/000162828026042504/sfix-20260502.htm . Strong put counterargument: profitable cash generation and retained liquidity support renewed recovery; call counterargument: repurchases exceed cash creation and gross-margin pressure offsets ticket growth. Client metric measures accounts active over52weeks, potentially multiple per person; it is not quarterly acquisition. Management benefits from highlighting adjusted EBITDA; shareholders need dilution/capex cash bridge. No target inferred from EBITDA multiple alone. Prior directional-neutral remains: the data permit both tails, not an estimate of event surprise. A new guide/client/FCF change may shift downside probability materially; honest prior only, not calibrated. Valuation/information cannot rescue a contract that fails its price test.